文献速递骨质疏松与代谢性骨病

双膦酸盐新使用者急性心肌梗死风险:巢式病例对照研究

Risk of acute myocardial infarction among new users of bisphosphonates: a nested case-control study.
PubMed 文献 · Osteoporos Int · 2020-07-14

在BIFAP数据库2002-2015年40-99岁人群中开展巢式病例对照研究,纳入23,590例急性心肌梗死(AMI)病例和117,612名对照,评估双膦酸盐新使用者与AMI风险的关联。当前使用双膦酸盐的调整比值比(AOR)为0.98(95%CI 0.854-1.14),近期和既往使用及不同治疗时长均未见风险降低。结果不支持双膦酸盐具有心脏保护作用,与治疗时长、年龄、性别或背景心血管风险无关;但作者指出若骨质疏松患者基线AMI风险较高,可能掩盖了小的保护效应。

要点

  • 当前使用双膦酸盐与AMI风险无显著关联,AOR 0.98(95%CI 0.854-1.14)。
  • 近期和既往使用双膦酸盐均未显示AMI风险降低。
  • 治疗时长不足1年AOR 0.92(95%CI 0.73-1.15),超过1年AOR 1.03(95%CI 0.86-1.23)。

核心结论

  • 结果不支持双膦酸盐具有心脏保护作用,与治疗时长、年龄、性别或背景心血管风险无关。
  • 作者指出,若骨质疏松患者基线AMI风险较高,可能掩盖了小的保护效应。

研究设计与样本

  • 巢式病例对照研究,基于BIFAP数据库2002-2015年40至99岁、注册至少1年的患者队列。
  • 从队列中识别新发AMI病例,按年龄、性别和索引日期精确匹配,每例随机选取5名对照。
  • 仅纳入双膦酸盐起始使用者,通过非条件logistic回归计算调整比值比(AOR)及95%CI。

主要发现

  • 共纳入23,590例AMI病例和117,612名对照,两组平均年龄66.8岁(SD 13.4),男性占72.52%。
  • 当前使用双膦酸盐者:病例276例(1.17%),对照1458名(1.24%),AOR 0.98(95%CI 0.854-1.14)。
  • 近期和既往使用双膦酸盐均与AMI风险降低无关。
  • 治疗时长不足1年AOR 0.92(95%CI 0.73-1.15),超过1年AOR 1.03(95%CI 0.86-1.23)。
  • 按年龄、性别和背景心血管风险分层分析未显示这些变量存在效应修饰。

局限性

  • 作者指出,若骨质疏松患者基线AMI风险较高,可能掩盖了小的保护效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To test the hypothesis that bisphosphonates reduce AMI risk among new users and to assess whether the effect depends on the duration of treatment. METHODS: Case-control study nested in a primary cohort composed of patients aged 40 to 99 years, with at least 1-year registry in the BIFAP database throughout the study period 2002-2015. Out of this cohort, incident AMI cases were identified and five controls per case were randomly selected, matched by exact age, sex, and index date. The association of AMI with current, recent and past use of bisphosphonates was assessed by computing adjusted odds ratios (AOR) and their corresponding 95% confidence interval (CI) through an unconditional logistic regression. Only initiators of bisphosphonates were considered. RESULTS: A total of 23,590 cases of AMI and 117,612 controls were included. The mean age was 66.8 (SD 13.4) years, and 72.52% was male, in both groups. About 276 (1.17%) cases and 1458 (1.24%) controls were current users of bisphosphonates yielding an AOR of 0.98 (95% CI 0.854-1.14). Recent and past use were not associated with a reduced risk, either, nor was it found a reduction with treatment duration (AOR less than 1 year = 0.92; 95% CI 0.73-1.15; AOR more than 1 year = 1.03; 95% CI 0.86-1.23). Stratified analysis by age, sex and background cardiovascular risk did not show an effect modification by these variables. CONCLUSION: The results do not support a cardioprotective effect of bisphosphonates regardless of the duration of treatment, age, sex or background cardiovascular risk. However, a small protective effect could have been masked if patients with osteoporosis have had a background higher risk of AMI.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Mazzucchelli R, Rodríguez-Martín S, García-Vadillo A, et al. Risk of acute myocardial infarction among new users of bisphosphonates: a nested case-control study. Osteoporos Int. 2020. PMID: 32662036. doi:10.1007/s00198-020-05538-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。